Could a simple injection replace major surgery for ovarian cancer staging?
NCT ID NCT06963268
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a sentinel lymph node technique, where a small amount of radioactive tracer and dye is injected to find the first lymph nodes that might contain cancer. In 200 women with early-stage ovarian cancer, doctors will compare this method to the standard approach of removing many lymph nodes. The goal is to see if the less invasive technique is accurate enough to replace the more extensive surgery, which could mean fewer side effects and faster recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sentinel lymph node technique (radioactive tracer and dye injection)
What this could lead to
If successful, this technique could replace extensive lymph node removal, reducing surgical complications and recovery time for early-stage ovarian cancer patients.
What could go wrong
This is a Phase 3 trial, but the technique may not be accurate enough to replace standard surgery, and there is a risk of missing cancer spread.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitario y Politécnico La Fe
RECRUITINGValencia, Valencia, 46026, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact